NP
AZN icon

NorthRock Partners’s AstraZeneca AZN Stock Holding History

NorthRock Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$657K Buy
3,462
+123
+4% +$23.1K 0.01% 383
2026
Q1 		$659K Buy
+3,339
New +$644K 0.01% 371
2025
Q4 		– Sell
-2,233
Closed -$343K – 647
2025
Q3 		$343K Sell
2,233
-53
-2% -$8.02K 0.01% 656
2025
Q2 		$319K Sell
2,286
-201
-8% -$28.2K 0.01% 517
2025
Q1 		$366K Buy
2,487
+646
+35% +$93.5K 0.01% 431
2024
Q4 		$241K Buy
1,841
+150
+9% +$21K 0.01% 532
2024
Q3 		$263K Buy
1,691
+25
+2% +$4.04K 0.01% 540
2024
Q2 		$260K Sell
1,666
-6
-0.4% -$903 0.01% 513
2024
Q1 		$227K Sell
1,672
-361
-18% -$47.8K 0.01% 552
2023
Q4 		$274K Buy
+2,033
New +$264K 0.01% 475
2023
Q3 		– Sell
-1,578
Closed -$226K – 355
2023
Q2 		$226K Sell
1,578
-69
-4% -$10.2K 0.02% 269
2023
Q1 		$229K Buy
+1,647
New +$222K 0.02% 282
2022
Q3 		– Sell
-3,884
Closed -$513K – 301
2022
Q2 		$513K Buy
3,884
+66
+2% +$8.66K 0.05% 150
2022
Q1 		$507K Buy
3,818
+292
+8% +$35K 0.05% 172
2021
Q4 		$411K Sell
3,526
-175
-5% -$20.6K 0.03% 200
2021
Q3 		$444K Buy
3,701
+471
+15% +$54.8K 0.04% 167
2021
Q2 		$387K Hold
3,230
– – 0.03% 167
2021
Q1 		$321K Sell
3,230
-2,073
-39% -$208K 0.03% 166
2020
Q4 		$530K Sell
5,303
-4,564
-46% -$483K 0.05% 123
2020
Q3 		$1.08M Buy
9,867
+6,832
+225% +$760K 0.12% 71
2020
Q2 		$321K Sell
3,035
-176
-5% -$18.2K 0.04% 151
2020
Q1 		$287K Sell
3,211
-1,011
-24% -$95.2K 0.04% 146
2019
Q4 		$421K Buy
4,222
+526
+14% +$49.5K 0.04% 169
2019
Q3 		$329K Buy
+3,696
New +$320K 0.04% 155

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NorthRock Partners's AZN Position: Q2 2026 in Review

NorthRock Partners increased its AstraZeneca (AZN) stake by 3.7% in Q2 2026, buying an estimated $23.1K and bringing the position to 3,462 shares worth $657K. The position accounts for 0.01% of the portfolio, ranked #383.

NorthRock Partners first reported a position in AZN in Q3 2019 and has held it in 24 quarters since. The position peaked at $1.08M in Q3 2020. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • NorthRock Partners held 3,462 shares of AstraZeneca worth $657K as of Q2 2026.
  • NorthRock Partners bought 123 AstraZeneca shares in Q2 2026, an estimated $23.1K.
  • AstraZeneca made up 0.01% of NorthRock Partners's portfolio in Q2 2026, its #383 holding.
  • NorthRock Partners first reported a position in AstraZeneca in Q3 2019 and has held it in 24 quarters since.
  • NorthRock Partners's AstraZeneca position peaked at $1.08M in Q3 2020.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on NorthRock Partners's 13F filing for Q2 2026, filed 11 Aug 2026.